RxDoctor Payments Data

Sumith Aleti, MD

Interventional Cardiology · Clermont, FLNPI 1629292875

Payments from drug & device makers

$30,832in general payments, 2019–2025

Across 442 payments — averaging $69.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$14K
  • Stryker$3K
  • Abiomed$2K
  • Shockwave Medical, Inc$2K
  • Medtronic$2K
  • Penumbra, Inc.$1K
  • plus $6K from 23 others

What the payments were for

  • Consulting fees$2,8009%
  • Speaking & faculty fees$12,40040%
  • Travel & lodging$1,7376%
  • Food & beverage$13,86545%
  • Education$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,832 in reported general payments places this provider in the 70th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$292,933
Medicare patients
1,040
Services billed
3,428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban453$481,993
XareltoRivaroxaban149$172,755
EntrestoSacubitril/Valsartan122$151,463
Repatha SureclickEvolocumab196$148,927
FarxigaDapagliflozin Propanediol64$65,345
JardianceEmpagliflozin28$43,766
BrilintaTicagrelor55$42,001
VascepaIcosapent Ethyl22$12,403
Icosapent Ethyl12$9,911
Praluent PenAlirocumab12$9,354
Metoprolol Succinate432$5,756
Atorvastatin Calcium502$4,828
ClopidogrelClopidogrel Bisulfate449$4,597
Dabigatran EtexilateDabigatran Etexilate Mesylate16$3,726
PradaxaDabigatran Etexilate Mesylate11$3,584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$46$481,993453 claims
Johnson & JohnsonXarelto$183$172,755149 claims
NovartisEntresto$447$151,463122 claims
AstraZenecaFarxiga, Brilinta$83$107,346119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Clermont

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →